Small Cell/Neuroendocrine
1 clinical trials · Condition
◉ Watch Small Cell/Neuroendocrine
| Record | Firm | Date |
|---|---|---|
| Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors (NCT04538378) | National Cancer Institute (NCI) | 2021-07-07 |
Track Small Cell/Neuroendocrine automatically
Every clearance here is in the API, with alerts when new ones post.